Purchase this article with an account.
Fumiki Okamoto, Yoshimi Sugiura, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika; Changes in metamorphopsia in patients undergoing treatment for various vitreoretinal disorders. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5048.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To quantify metamorphopsia in patients undergoing vitrectomy or anti-VEGF injection for various vitreoretinal disorders and to compare the changes in metamorphopsia among vitreoretinal disorders.
We studied 339 patients with various vitreoretinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch retinal vein occlusion (BRVO-CME), CME with central retinal vein occlusion (CRVO), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), macula-on RD (M-on RD), and type 1 idiopathic macular telangiectasia (Mactel). The severity of metamorphopsia was recorded using the M-CHARTS preoperatively and at 3 and 6 months postoperatively.
In all patients, the mean metamorphopsia scores before, 3, 6 months after treatment were 0.67 ± 0.49, 0.52 ± 0.52, 0.50 ± 0.52, respectively. Most of patients (95%) had metamorphopsia (metamorphopsia score ≥ 0.2) preoperatively. The preoperative metamorphopsia score was significantly correlated with the postoperative metamorphopsia score (r = 0.45, p < 0.0001). The preoperative metamorphopsia score in ERM (0.88) were significantly higher than those in DME (0.51) and Mactel (0.48). Vitrectomy improved metamorphopsia in ERM and MH, but not in other disorders. On the other hand, visual acuity improved by treatment in all disorders except CRVO-CME. Metamorphopsia scores at 3 months postoperatively in M-off RD were significantly higher than those in M-on RD. However, there were no differences in metamorphopsia between 3 and 6 months postoperatively in M-off RD and M-on RD.
Most of patients in the current study showed metamorphopsia before treatment. Metamorphopsia in ERM was severer than that in other disorders. In majority of vitreoretinal disorders, treatment improved visual acuity, but not metamorphopsia.
This PDF is available to Subscribers Only